Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $20,308 | 4 | 98.8% |
| Food and Beverage | $209.58 | 4 | 1.0% |
| Education | $30.00 | 1 | 0.1% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ACADIA Pharmaceuticals Inc | $20,308 | 4 | $0 (2018) |
| Exelixis Inc. | $102.98 | 1 | $0 (2017) |
| Biogen, Inc. | $63.47 | 1 | $0 (2019) |
| Eisai Inc. | $30.00 | 1 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $25.45 | 1 | $0 (2019) |
| Mallinckrodt LLC | $17.68 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $30.00 | 1 | Eisai Inc. ($30.00) |
| 2019 | $88.92 | 2 | Biogen, Inc. ($63.47) |
| 2018 | $13,808 | 3 | ACADIA Pharmaceuticals Inc ($13,808) |
| 2017 | $6,621 | 3 | ACADIA Pharmaceuticals Inc ($6,500) |
All Payment Transactions
9 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/07/2023 | Eisai Inc. | Leqembi (Drug) | Education | Cash or cash equivalent | $30.00 | General |
| Category: Neurology | ||||||
| 12/05/2019 | Biogen, Inc. | — | Food and Beverage | Cash or cash equivalent | $63.47 | General |
| 07/17/2019 | Novartis Pharmaceuticals Corporation | API015 (Drug) | Food and Beverage | In-kind items and services | $25.45 | General |
| 06/05/2018 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | — | Cash or cash equivalent | $2,936.25 | Research |
| Study: ACP-103-045 • Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 05/16/2018 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | — | Cash or cash equivalent | $3,684.38 | Research |
| Study: ACP-103-045 • Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 03/16/2018 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | — | Cash or cash equivalent | $7,187.63 | Research |
| Study: ACP-103-045 • Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 12/20/2017 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | — | Cash or cash equivalent | $6,500.00 | Research |
| Study: ACP-103-045 • Category: PDP | ||||||
| 04/05/2017 | Mallinckrodt LLC | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $17.68 | General |
| Category: AUTOIMMUNE AND RARE DISEASE | ||||||
| 01/19/2017 | Exelixis Inc. | Cabometyx (Drug) | Food and Beverage | In-kind items and services | $102.98 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ACP-103-045 | ACADIA Pharmaceuticals Inc | $20,308 | 4 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 192 | 343 | $74,515 | $20,279 |
| 2022 | 4 | 198 | 303 | $47,795 | $20,120 |
| 2021 | 4 | 197 | 286 | $49,710 | $23,063 |
| 2020 | 4 | 169 | 179 | $47,135 | $18,803 |
All Medicare Procedures & Services
15 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 81 | 104 | $43,400 | $11,878 | 27.4% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 83 | 211 | $16,700 | $4,573 | 27.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 28 | 28 | $14,415 | $3,829 | 26.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 76 | 93 | $24,645 | $11,447 | 46.4% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2022 | 78 | 166 | $10,790 | $3,961 | 36.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 21 | 21 | $7,875 | $2,910 | 37.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 23 | 23 | $4,485 | $1,802 | 40.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 95 | 119 | $31,535 | $15,631 | 49.6% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2021 | 72 | 137 | $8,905 | $3,476 | 39.0% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 19 | 19 | $7,125 | $3,059 | 42.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 11 | 11 | $2,145 | $897.99 | 41.9% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 100 | 110 | $29,150 | $10,915 | 37.4% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 26 | 26 | $9,750 | $3,839 | 39.4% |
| 99354 | Prolonged office or other outpatient service first hour | Office | 2020 | 30 | 30 | $5,700 | $3,021 | 53.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 13 | 13 | $2,535 | $1,029 | 40.6% |
About Dr. Roberto Fernandez-Romero, M.D
Dr. Roberto Fernandez-Romero, M.D is a Neurology healthcare provider based in Knoxville, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1194839639.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Roberto Fernandez-Romero, M.D has received a total of $20,548 in payments from pharmaceutical and medical device companies, with $30.00 received in 2023. These payments were reported across 9 transactions from 6 companies. The most common payment nature is "" ($20,308).
As a Medicare-enrolled provider, Fernandez-Romero has provided services to 756 Medicare beneficiaries, totaling 1,111 services with total Medicare billing of $82,266. Data is available for 4 years (2020–2023), covering 15 distinct procedure/service records.
Practice Information
- Specialty Neurology
- Location Knoxville, TN
- Active Since 08/19/2006
- Last Updated 06/11/2025
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1194839639
Products in Payments
- NUPLAZID (Drug) $20,308
- Cabometyx (Drug) $102.98
- Leqembi (Drug) $30.00
- API015 (Drug) $25.45
- ACTHAR (Biological) $17.68
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Knoxville
Sibyl Wray, Md, MD
Neurology — Payments: $3.1M
Dr. David Brandes, Md, MD
Neurology — Payments: $1.1M
Randall Trudell, M.d, M.D
Neurology — Payments: $152,917
Michelle Brewer, M.d, M.D
Neurology — Payments: $127,026
Dr. Rosanne Barker, Md, MD
Neurology — Payments: $28,703
Dr. Samir Al-Kabbani, Md, MD
Neurology — Payments: $23,480